Background Recent efforts in malaria control have resulted in great gains in reducing the
burden of Plasmodium falciparum, but P. vivax has been more refractory. Its ability to form …

Plasmodium vivax is the second most important cause of morbidity in Ethiopia. There is,
however, little information on P. vivax resistance to chloroquine and chloroquine plus …

Background In vivo efficacy assessments of antimalarials are essential for ensuring effective
case management. In Ethiopia, chloroquine (CQ) without primaquine is the first-line …

Afghanistan's national guidelines recommend primaquine (PQ) for radical treatment of
Plasmodium vivax malaria, but this is rarely implemented because of concerns over …

Background Plasmodium vivax malaria is still an important public health problem in
Ethiopia. Unlike Plasmodium falciparum, P. vivax has a dormant liver stage (hypnozoite) that …

Background Primaquine is the only widely used drug that prevents Plasmodium vivax
malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to …

Chloroquine (CQ) is a relatively inexpensive drug for treatment of malaria. If efficacy of CQ is
still assumed, then it should be indicated in malaria treatment policies as the drug of choice …

Background Plasmodium vivax malaria, with the widest geographic distribution, can cause
severe disease and death. Primaquine is the main licensed antimalarial drug that can kill …

Background Chloroquine (CQ) is the first-line treatment for vivax malaria in Ethiopia, but
there is evidence for its declining efficacy. Defining the extent and regional distribution of CQ …

Background Primaquine is used to eliminate Plasmodium vivax hypnozoites, but its optimal
dosing regimen remains unclear. We undertook a systematic review and individual patient …